Oncolytic virotherapy with conditionally replicating viruses is a promising approach for treating advanced cancers. Promiscuous tropism and low tumor transduction have represented limiting issues, which targeting approaches seek to overcome. An approach utilizing a secretory targeting molecule for the epidermal growth factor pathway (sCAR-EGF) has previously been shown to be compatible with replicating adenoviruses, when an E1-deleted vector was used in a dual-virus system in conjunction with a replication-competent agent. Here, we constructed a virus that replicates in cancer cells and codes for sCAR-EGF. Interestingly, the oncolytic potency of the novel agent was not improved over nontargeted controls in vitro or in vivo. These results suggest that the expression of biologically active proteins can be counterproductive to virus replication.
O ncolytic viruses, which are replication competent in tumor but not in normal tissues, have emerged as an exciting approach for treatment of cancers refractory to available treatments. Clinical results have indicated the safety of the approach, but evidence of efficacy has been limited, albeit few Phase II and no Phase III trials have been published. Nevertheless, it has become clear that effective tumor transduction is the key to efficacy, while limiting oncolysis to tumor tissue determines toxicity. Tumor targeting has the potential for improving both attributes and various approaches have undergone preclinical evaluation. 1 In the context of oncolytic viruses, a requirement for targeting molecules is genetic incorporation into the virus genome, as pretargeting approaches would not benefit subsequent rounds of replication. We have previously shown that a fusion molecule between CAR and EGF (sCAR-EGF) is secretory from human cells and can retarget replication-competent and -deficient viruses to EGFR. 2, 3 This increased the transduction, gene transfer and cell killing of high EGFR targets while reducing CAR-mediated gene transfer. Both aspects are important as CAR expression is a major factor determining transduction with adenovirus serotypes 2 and 5, but has shown to be quite variable on tumor tissues, including ovarian, colorectal, lung, prostate, breast, bladder, head and neck cancer, glioma, melanoma and others, while CAR is ubiquitously expressed on most normal epithelial tissues (reviewed in Hemminki and Alvarez 1 ). EGFR is a classic tumor-associated receptor and commonly overexpressed in many carcinomas, with correlation to metastatic behavior and poor prognosis, and could therefore be useful for targeting approaches. 4 Therefore, blocking virus-CAR interactions while increasing EGFRmediated entry could improve transduction of tumor tissue while sparing normal tissues. Our previous cell killing and in vivo data were obtained with a dual-virus system, where replication selectivity was conferred by one virus and the targeting protein by another. 3 While useful for testing hypotheses, such a system may have pharmacodynamic and pharmacokinetic complexities undesirable for clinical application. Therefore, we constructed and tested a single-component system. In contrast to our previous findings, this virus was not increased in oncolytic potency in vitro or in vivo.
Materials and methods

Construction of D24sCAR-EGF
pShuttle-CMV-sCAR-EGF 3 was digested with MscI and SacI, followed by ligation of the CMV-sCAR-EGF-polyA fragment into the AatII site of pKO3A (Fig 1) . Restriction enzyme analysis and PCR were performed to confirm the structure.
GAATAAGAGGAAGT-GAAATCTGA and TAGCGATGACTAATACGTA-GATG were used to amplify a 403 bp fragment overlapping CMV and sCAR, CAACTGTGTTGTTG-GCTACAT and AAGATACATTGATGAGTTTGGAC to amplify a 401 bp fragment overlapping EGF and the polyA, TGAAACACCTGGTCCACTG and CTGCAA-CAACATGAAGATAGTG anneal to the homology regions (black areas in Fig 1a) and amplify the whole insert (2431 bp). D24 is an oncolytic adenovirus with a 24 bp deletion in CR2 of E1A. 5, 6 D24 DNA was purified with phenol-chloroform and digested with PacI (Fig 1) . The fragments were gel purified and cotransfected (Effectenet, Qiagen, Valencia, CA) with linearized pKO3A-CMV-sCAR-EGF-polyA into A549 cells as recommended. Briefly, cells were allowed to reach 80% confluency. A measure of 1 mg of DNA and 8 ml of enhancer were incubated in 200 ml for 5 minutes in R/T. Effectene Transfection Reagent (25 ml) was added to the mixture for 10 minutes in R/T. Then the complex was added to wells containing growth medium. The cells were overlayed with agarose and incubated until single plaques could be picked. Two rounds of plaque purification were performed. The presence and structure of the transgene were confirmed with PCR as above. The third primer pair yields a 500 bp fragment in the presence of virus without an insert in E3, thus confirming the absence of wild-type D24.
Propagation of viruses and cells
AdsCAR-EGF and Ad5Luc1 are E1-deleted viruses expressing sCAR-EGF and luciferase, respectively. 3, 7 D24-CMV-TGL (T H, manuscript in preparation) is isogenic to D24sCAR-EGF with regard to the control elements, but the transgene is a fusion protein between thymidine kinase and GFP. 8 Large-scale virus production of oncolytic viruses was performed on A549 cells followed by purification with double cesium chloride gradients. Functional and physical titering were performed with plaque assay or TCID50 and OD260, respectively. D24sCAR-EGF yielded 2 Â 10 13 viral particles (VP)/ml and 1 Â 10 10 TCID50/ml, D24-CMV-TGL 3 Â 10 12 VP/ml and 5 Â 10 10 PFU/ml, D24 8.3 Â 10 12 VP and 1.2 Â 10 11 PFU/ml. A549 (lung cancer), BT474 (breast cancer), HeLa (cervical adenocarcinoma), U118 (glioblastoma) and A431 (epidermoid carcinoma) were obtained from ATCC (Rockville, MD) and SKOV3.ip1 cells (ovarian cancer) are from Dr Janet Price (MD Anderson Cancer Center, Houston, TX). Cells were propagated as recommended.
Protein and mRNA detection
Western blots were performed as previously. 3 Briefly, BT474 cells were infected with 1000 VP/cell of AdsCAR-EGF, D24sCAR-EGF and Ad5Luc1. Supernatants and cells were collected as indicated. Cellular debris in the supernatants was removed by centrifugation. Samples were boiled in Laemmli buffer and subjected to 12% SDS-PAGE electrophoresis. Nonfat milk (5%) was used for blocking, and probing was performed with a polyclonal mouse anti-CAR antibody (1:1000). 3 Bound IgG was detected in 5% nonfat milk with a goat antimouse-IgG conjugated to horseradish peroxidase (1:30,000) (Jackson ImmunoResearch, West Grove, PA), which was imaged with the ELC system (Western Blot Chemiluminescence Reagent Plus, NEN Life Science Products, Boston, MA). Baculovirus-expressed sCAR-EGF 2 was used as a positive control. Quantitative RT-PCR for sCAR-EGF was performed with primers: forward: AAATTTACGCTTAGTCCCGAAGAC, reverse: 
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Cell killing assays
HeLa, SKOV3.ip1, U118 and A431 cells were infected for 3 hours, followed by replacement of infection medium (2% FBS) with growth medium (10% FBS). A set of experiments were also performed, where viruses were mixed with sCAR-EGF containing supernatant, as previously. 3 The medium was replaced every 48 hours until almost complete cell killing was seen for the lowest dose of control virus (D24 or D24-CMV-TGL). Then, cells were fixed with formalin and stained with crystal violet (1% in 70% EtOH) to detect live cells. The experiment shown in Figure 2 was allowed to proceed longer for the D24sCAR-EGF groups, in order to detect cell killing. injections were given (days 1-3). Viruses were diluted with OptiMEM (UAB Media Shared Facility, Birmingham, AL) into 50 ml. Tumor size was measured in the longest and shortest diameter and the volume was calculated:
Murine model of EGFR-expressing cancer
. Each group consisted of five mice, each with two tumors. The analysis of the tumor size data was performed using a repeated measures growth model with PROC MIXED (SAS v. 8.02, SAS Institute, Cary, NC), which treated the within mouse effect of time as a continuous variable and the treatment group as a fixed effect. The tumor size data was log transformed for normality. The observed curvature in the tumor growth data by time was included in the model as a quadratic term. The effects of treatment group, time and the interaction of treatment group and time were evaluated by F tests. Baseline tumor size was included as a covariate. The a priori planned comparisons of differences in predicted treatment means were computed by tstatistics, averaged over all time points and for day 21 alone. Although only preplanned comparisons were employed, Tukey-Kramer adjustment was utilized to allow for multiple comparisons.
Results
sCAR-EGF production by D24sCAR-EGF
At 48 and 72 hours, low amounts of sCAR-EGF could be detected in cells infected with D24sCAR-EGF, but not in the supernatant (Fig 1b) . In contrast, sCAR-EGF could be detected in the supernatant and cells infected with AdsCAR-EGF. The experiment was repeated four times with identical results. As previously, 3 the baculovirusproduced sCAR-EGF migrated slightly faster in the gel than the mammalian cell-produced sCAR-EGF. In quantitative RT-PCR, AdsCAR-EGF resulted in 105-, 323-and 305-fold higher sCAR-EGF expression in comparison to D24sCAR-EGF at 24, 48 and 72 hours, respectively (Fig 1c) .
Cell killing by D24sCAR-EGF in vitro
Cell lines expressing moderately elevated (U118, SKO-V3.ip1) or high (HeLa, A431) levels of EGFR were infected with D24sCAR-EGF and D24. To allow comparison to previous experiments performed with dualvirus systems secreting sCAR-EGF, 3 both viruses were mixed with sCAR-EGF-containing supernatant before infection. Interestingly, D24 killed cells more effectively than D24sCAR-EGF. This was true even when replication of D24sCAR-EGF was allowed to proceed 5 days longer than D24 (Fig 2) . When the experiment was performed without preincubation with sCAR-EGF-containing supernatant, the results were the same (not shown). Next, D24sCAR-EGF was compared to D24-CMV-TGL, a virus otherwise identical to D24sCAR-EGF, but containing a different transgene (Fig 3) . Again, D24sCAR-EGF was less effective in cell killing with 3/4 lines. With A431 cells, which express high levels of EGFR, 2 the difference between D24sCAR-EGF and Figure 2 Cell killing experiments with D24sCAR-EGF and D24, the isogenic control virus without a transgene. Triplicate wells were infected with 0, 10, 100 or 1000 VP/cell and cell killing was allowed to proceed for 8 days, followed by crystal violet staining to detect live cells. Cells infected with D24sCAR-EGF were incubated for 5 days longer as little cell killing was evident at 8 days.
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controls was less pronounced. The differences seen between HeLa and A431 could be due to relative expression levels of molecules relevant for entry, such as EGFR, CAR and a v b-class integrins, or due to differential sensitivity to EGF-mediated cell cycle effects (see below).
Therapeutic efficacy of D24sCAR-EGF in an animal model of EGFR-expressing cancer
A431 tumors were inoculated s.c. in mice and viruses were injected i.t. (Fig 4) . In accord with the in vitro data, D24sCAR-EGF gave an antitumor effect similar to D24 or D24-CMV-TGL. In the statistical analysis, D24sCAR-EGF resulted in significantly improved antitumor efficacy over no virus (OptiMEM, Po.0001) or an E1-deleted virus (Ad5Luc1, Po.0001). The same values were obtained in both the overall analysis, the analysis restricted to day 21 and in the Tukey-Kramer-adjusted analyses. The therapeutic efficacy of D24sCAR-EGF was not different from D24 or D24-CMV-TGL (all P-values 4.3, Tukey-Kramer-adjusted values 4.8). D24 and D24-CMV-TGL gave a significant therapeutic effect over the controls (all Tukey-Kramer-adjusted P-values o.0001).
Discussion
Targeting adenovirus to tumor cells is a useful way for increasing transduction of target tissue while decreasing side effects and toxicity. One approach is the use of secretory adaptor molecules. 3 Previously, we constructed a replication-deficient virus coding for sCAR-EGF, which induced infected cells to produce and secrete the fusion protein into the supernatant. Further, when coinfected with a replication-competent virus, increased cell killing was seen in comparison to a similar two-virus system not secreting sCAR-EGF. 3 Here, we constructed a singlecomponent oncolytic agent, D24sCAR-EGF, which incorporates expression cassette in the deleted E3 region (Fig 1a) . Cells infected with the agent were shown to produce lower amounts of sCAR-EGF than AdsCAR-EGF-infected cells (Fig 1b,c) . Previous reports have indicated that transgene expression is amplified in Figure 3 Cell killing experiments with D24sCAR-EGF and D24-CMV-TGL, the isogenic control virus with identical control elements but an unrelated transgene. Triplicates of cells were infected with 0, 10, 100 or 1000 VP. For each cell line, cell killing was allowed to proceed until almost complete cell killing was evident with D24-CMV-TGL at 10 VP/cell, followed by crystal violet staining to detect live cells. Figure 4 Antitumor effect of D24sCAR-EGF in a murine model of cancer expressing high EGFR. A431 cells were inoculated s.c., followed by i.t. injection of D24sCAR-EGF, the replication-competent controls (D24-CMV-TGL and D24), a replication-deficient control (Ad5Luc1) or no virus (OptiMEM). D24sCAR-EGF gave a significantly improved therapeutic effect over Ad5Luc1 and OptiMEM (Po.0001, Tukey-Kramer-adjusted t-test). The therapeutic efficacy of D24sCAR-EGF was similar to D24-CMV-TGL and D24 (P4.8, Tukey-Kramer-adjusted t-test). Errors bars indicate SE. N ¼ 5 mice/ group, two tumors/mouse.
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Interestingly, D24sCAR-EGF was less effective in cell killing than D24, which is otherwise isogenic but does not incorporate a transgene (Fig 2) . Further, in 3/4 cell lines, D24sCAR-EGF was less effective than D24-CMV-TGL, which is identical to D24sCAR-EGF except that the transgene is different (Fig 3) . This suggested that the lower oncolytic potency of D24sCAR-EGF was not due to transgene expression per se, but specifically related to sCAR-EGF. Interestingly, this seems to be in contrast with results obtained previously with the two-virus system on A431 and SKOV3.ip1 cells. 3 The reasons for this may be related to the complexities of the two-virus system: a subpopulation of cells may have been infected just with AdsCAR-EGF and effectively produced sCAR-EGF, which mediated retargeting of the oncolytic virus for enhanced cell killing.
EGF is an important signaling molecule with diverse regulatory functions related to growth, communication and development. 4 Therefore, it is not easy to identify the exact mechanisms whereby intracellular production of sCAR-EGF would result in reduced cell killing. As EGF is a strong mitogen, 4 one possibility could be the production of sCAR-EGF to such concentrations that cell division is balanced against cell killing. This may be unlikely as the amplification provided by virus replication and burst would probably overcome even expedited cell division. Further, D24sCAR-EGF produces less sCAR-EGF than AdsCAR-EGF and thus the aforementioned effect would have been more clearly detectable with the dual-virus system. 3 However, if EGF has an immortalizing effect on cells, this could compromise viral burst and thus abrogate effective oncolysis.
Alternatively, sCAR-EGF may be specifically counteracting mechanisms that adenoviral E1 products employ for induction of S-phase, required for the effective production of viral proteins. Crucial for S-phase induction is binding and inactivation of Rb. 11 However, the 24 bp E1A deletion of D24sCAR-EGF disables Rb binding, but replication is possible in cells inactive in the Rb pathway. 5 Most, if not all, cancer cells are deficient in this crucial pathway responsible for regulation of the G 1 -S checkpoint.
12 Sometimes this is due to mutation of Rb, but more often another gene in the pathway is aberrant, resulting in phosphorylation of Rb and release of E2F, which drives replication of the cell. 12 Interestingly, studies with A431 cells have shown that EGF can dephosphorylate Rb resulting in G 1 arrest. 13 Thus, if this phenomenon is not restricted to A431 cells, it could be a mechanism whereby virus production is compromised due to incapability of S-phase induction. Nevertheless, we cannot exclude the possibility that sCAR-EGF production was partially responsible for the antitumor effect seen with D24sCAR-EGF on A431 cells.
Although the diverse actions of EGF converge on synergistic and antagonistic pathways, which can lead to either growth repression or stimulation, EGF has frequently been identified as a growth-promoting factor, often featuring autocrine growth loops. 4 The resulting powerful mitogenic signal may be able to promote progression through S into G 2 and M, which could compromise the adenovirus' purpose of locking the cell into S-phase. This hypothesis is supported by the low secretion of sCAR-EGF (Fig 1b,c) , which could partially be due to ineffective S-phase induction. The effects of EGF downstream from the G 1 -S checkpoint are not well understood, but some evidence exists for stimulation of cycling through S into G 2 -and M-phases. 14 This effect may be mediated in part by cyclins. 12, 15 More studies are clearly needed to clarify the relationship between EGF signaling pathways, adenovirus replication and transgene expression. However, the fact that proteins coded from both the E1 and E3 regions of adenovirus downregulate EGFR suggests that abrogation of EGFR signaling may be advantageous for virus replication, [16] [17] [18] [19] [20] and that production of EGFR-stimulating molecules could therefore be counterproductive to viral oncolysis.
In summary, data reported previously 2, 3 suggest that the extracellular presence of sCAR-EGF per se does not affect viral replication, alter cell cycle kinetics or activate the EGF receptor in a manner that would adversely affect replication. In contrast, in this paper we show that when sCAR-EGF is coded by a replication-competent agent, resulting in the dual intracellular processes of transgene expression and virus replication in the same cell, sCAR-EGF production is dramatically reduced in comparison to AdsCAR-EGF (Fig 1) . This suggests that processes involved in virus replication and sCAR-EGF production, when temporally and spatially associated, adversely affect virus replication and subsequent oncolysis. As the purpose of the project was to develop oncolytic agents that could be used for treatment of human cancer, the most relevant end point is killing the cancer cells (Figs 2-4) . Figure 2 suggests that both replication and oncolysis (oncolysis being the product of productive replication) are reduced due to intracellular expression of sCAR-EGF, in comparison to an identical virus not coding the transgene. Figure 3 shows a similar experiment with a control virus coding for a non-EGF transgene. In both instances, sCAR-EGF production was identified as the likely reason for reduced replication and oncolysis.
Our results suggest that incorporation of sCAR-EGF into a replication-competent adenovirus does not improve oncolytic potency. However, the approach could be beneficial, if there were an improvement in selectivity. Unfortunately, this is difficult to test as there are no model systems available that would allow replication of human serotype adenoviruses. If the reduction of oncolytic potency is due to biological activity of the adaptor, the phenomenon will probably not apply to all retargeting motifs. Heretofore, sCAR-EGF is the only adaptor that has been reported secretory from human cells. 3 However, studies on similar adaptors have been initiated. 21, 22 Further, antibody fusion molecules, diabodies and bispecific antibodies have been investigated. If some of these can be rendered secretory, it may be possible to achieve retargeting without reduction in oncolytic potency.
In conclusion, we developed a replication-competent oncolytic adenovirus producing sCAR-EGF. In vitro, the oncolytic potency was not improved over controls either lacking a transgene or incorporating a different transgene. In vivo, the novel agent was comparable to the oncolytic controls. The lack of improvement over untargeted adenoviruses may be due to the properties of sCAR-EGF interfering with virus production and oncolysis. These results may help to clarify the interplay between EGFR signaling and adenovirus replication.
